Table I.

Characteristics of included studies

References	Year	Country	Study design	Tumor size [cm]a	Age [years]a	Lesion type	Sample size			NOS
							Total	3D	2D
Yamanaka et al.	2007	Japan	RCS	NA	NA	ML	226	113	113	7
Pianka et al.	2011	Germany	RCS	9.5 ±3.6/ 10.4 ±3.8	50 ±10.6/ 48 ±10.0	ML	26	13	13	7
Fang et al.	2013	China	RCS	NA	50.6 ±11.5/ 53.5 ±12.6	BL	98	56	42	9
Begin et al.	2014	Canada	RCS	NA	61.6 ±12.9/ 64.8 ±16.8	ML	72	36	36	7
Fang et al.	2015	China	RCS	7.6 ±2.8/ 7.4 ±2.6	47.5 ±13.8/ 46.5 ±13.3	ML	116	60	56	8
He et al.	2015	China	RCS	NA	41.4 ±13.1/ 42.5 ±13.2	BL	106	59	47	9
Wei et al.	2015	China	RCS	9.5 ±3.6/ 10.4 ±3.8	50 ±10.6/ 48 ±10.0	ML	74	31	43	8
Su et al.	2016	China	RCS	NA	NA	ML	26	16	10	8
Zhang et al.	2019	China	RCS	NA	55.7 ±11.2/ 52.5 ±12.1	ML	64	30	34	9

^aExperimental group/control group.

ML – malignant lesions, BL – benign lesions, NOS – Newcastle-Ottawa Scale, NA – not available.